TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02379156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Hydrochloride
Description: Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the vascular-constricting effects of this drug will help keep warm blood closer to the body's core and improve the ability to maintain Tcore in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only (Visit 2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cool Temperature
Description: Subjects will be exposed to a routinely encountered cool temperature (64° F) for up to to 2 hours depending on the vital signs (BP, HR, Tcore) and tolerance (comfort).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cool Temperature
Description: Subjects will be exposed to a routinely encountered cool temperature (64° F) for up to to 2 hours depending on the vital signs (BP, HR, Tcore) and tolerance (comfort).
Study: NCT03900650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcoholic beverage
Description: Participants will consume an alcoholic beverage (vodka mixed with fruit juice) that is the equivalent of 3-4 standard alcoholic drinks based on their body weight.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcoholic beverage
Description: Participants will consume an alcoholic beverage (vodka mixed with fruit juice) that is the equivalent of 3-4 standard alcoholic drinks based on their body weight.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-alcoholic beverage
Description: Participants will consume a nonalcoholic beverage (fruit juice) that is the isovolemic equivalent of 3-4 standard alcoholic drinks based on their body weight.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-alcoholic beverage
Description: Participants will consume a nonalcoholic beverage (fruit juice) that is the isovolemic equivalent of 3-4 standard alcoholic drinks based on their body weight.
Study: NCT03508583

Intervention type: OTHER
Intervention: Participation
Description: The mpoc 56 and mpoc 20 will be field-tested with a sample of 300 parents of children with disabilities residing in the Turkey.~Professionals working with children with disabilities will be assessed with MPOC SP questionnaires
Study: NCT04573504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Augmentin/Flagyl or Augmentin/Clindamycin
Description: Women who suffer a severe vaginal laceration at Prentice Women's Hospital will be randomized to receive 5-days of oral antibiotics or placebo pills after getting a standard one-time dose of IV antibiotics at the time of repair.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04148209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: Participants will receive single ascending doses PF-07081532

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo
Study: NCT04569032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg daily administered orally on Days 1-5 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg daily administered orally on Days 1-5 of each cycle
Study: NCT00778544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension
Study: NCT01969409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: i.v. rituximab given on two occasions 14 days apart.
Study: NCT03968861

Intervention type: DRUG
Intervention: Xenon
Description: Inhaled xenon gas given via purposely designed ventilator
Study: NCT04290650

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Modified CBT for insomnia
Description: Nurses who are working closely with the patients around the clock will perform an adjusted and modified version of CBT for sleep disturbances, in addition to standard evidence based treatment for psychosis and affective disorders as per today.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: All patients on the two other psychosis wards will receive standard evidence based treatment for psychosis and affective disorders as per today.
Study: NCT04755543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP002
Description: 600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP002
Description: 600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W).
Study: NCT01969409

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.
Study: NCT05068583

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood draw at baseline, disease evaluation time point, and pre and post surgery and/or radiation.

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood draw at baseline, disease evaluation time point, and pre and post surgery and/or radiation.

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood draw at baseline, disease evaluation time point, and pre and post surgery and/or radiation.

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood draw at baseline, disease evaluation time point, and pre and post surgery and/or radiation.

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood draw at baseline, disease evaluation time point, and pre and post surgery and/or radiation.

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood draw at baseline, disease evaluation time point, and pre and post surgery and/or radiation.

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood draw at baseline, disease evaluation time point, and pre and post surgery and/or radiation.

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood draw at baseline, disease evaluation time point, and pre and post surgery and/or radiation.

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood draw at baseline, disease evaluation time point, and pre and post surgery and/or radiation.

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood draw at baseline, disease evaluation time point, and pre and post surgery and/or radiation.
Study: NCT03000881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard adhesive
Description: This is a standard adhesive (hydrocolloid)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New adhesive strip
Description: This is a newly developed adhesive strip
Study: NCT04282785

Intervention type: DIAGNOSTIC_TEST
Intervention: Concentration monitoring of antibiotics in plasma
Description: Plasma antibiotic concentration will be measured using a bedside method with UV-VIS spectroscopy. These measurements will be validated with golden standard that is HPLC-MS.
Study: NCT04539288

Intervention type: OTHER
Description: There is no intervention in this study.
Study: NCT00585312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: celecoxib, 16 mg/kg/day, for 5 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Masked, placebo comparator
Study: NCT04256707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor 100 mg
Description: 100-mg 2 formulations:~* 5 × 20-mg tablets (Tablet A)~* 1 × 100-mg tablet (Tablet B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 IV
Study: NCT04755543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP002
Description: 600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50mg/m2 IV on Day 1, Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50mg/m2 IV on Day 1, Q2W
Study: NCT01202084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol/Fluticasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foraseq®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Study: NCT03898427

Intervention type: DEVICE
Intervention: Wrist Actigraphy Devices
Description: A watch-like wearable sensor

Intervention type: DEVICE
Intervention: Polysomnography
Description: Sleep Monitor

Intervention type: DEVICE
Intervention: Videography
Description: Thermal Camera
Study: NCT02474498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMD
Description: During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMD
Description: During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: βTCP/HA
Description: During flap access surgery, the granulation tissue will be removed and the root surfaces were carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: βTCP/HA
Description: During flap access surgery, the granulation tissue will be removed and the root surfaces were carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flap access surgery
Description: In the furcation sites, during flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flap access surgery
Description: In the furcation sites, during flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments.
Study: NCT04755543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OH2 oncolytic virus
Description: 106 or 107 or 108 CCID50/mL by intra-tumoral injection, Q2W
Study: NCT02474498

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flap access surgery
Description: In the furcation sites, during flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments.
Study: NCT03453216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neuropsychological tests
Description: Part 1: to determine the cognitive capacity, the subjects undergo different neuropsychological tests To determine individual characteristics children, adolescents and adults complete self-assessment questionnaires .~Adults spend a semi-directive interview. Part 2: while the subject 1 (S1) is installed in the MRI, he perform behavioral tasks with the subject 2 (S2) (familiar peer of the same age ± 2 years) installed in an adjacent room, alternating periods when S1 is observed by S2 (condition Social) and periods when S1 is not observed by S2 (condition Alone).
Study: NCT04942145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality in dental patients
Description: The behavioral anxiety response of dental patients (with and without virtual reality) related to psychological factors is studied.~Participants self-complete the questionnaires
Study: NCT02053220

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Colo-Ad1
Description: Oncolytic virus
Study: NCT04942145

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: virtual reality in dental patients
Description: The behavioral anxiety response of dental patients (with and without virtual reality) related to psychological factors is studied.~Participants self-complete the questionnaires
Study: NCT01833078

Intervention type: DRUG
Group type: OTHER
Intervention: ghrelin
Description: ghrelin administration subcutaneously for 7 days
Study: NCT02652247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: molecular analysis of exhaled breath condensate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: molecular analysis of exhaled breath condensate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: molecular analysis of exhaled breath condensate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: molecular analysis of exhaled breath condensate
Study: NCT04256707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI:~* Irinotecan 180 mg/m\^2~* Leucovorin 400 mg/m\^2~* 5-FU 400 mg/m\^2 bolus~* 5-FU 2400 mg/m\^2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor 40 mg
Description: - 2 × 20-mg tablets (Tablet A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor 40 mg
Description: - 2 × 20-mg tablets (Tablet A)
Study: NCT02652247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: molecular analysis of mini-bronchoalveolar lavage (BAL) aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: molecular analysis of mini-bronchoalveolar lavage (BAL) aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: molecular analysis of mini-bronchoalveolar lavage (BAL) aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: molecular analysis of mini-bronchoalveolar lavage (BAL) aspirate
Study: NCT04256707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor 80 mg
Description: - 4 × 20-mg tablets (Tablet A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor 80 mg
Description: - 4 × 20-mg tablets (Tablet A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor 60 mg
Description: - 3× 20-mg tablets (Tablet A)
Study: NCT02508116

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2C19 genotyping
Description: The study utilizes a genotyping device, SpartanRx™ (Spartan Bioscience, Ottawa, Canada) that provides identification of a patient's CYP2C19 \*2, \*3, and \*17 genotypes determined from genomic DNA from a buccal swab sample with 1 hour turnaround time
Study: NCT02056652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioteque cup pessary
Study: NCT03889691

Intervention type: PROCEDURE
Intervention: Third molar surgery
Description: Surgical extraction of impacted lower third molar tooth under local anesthesia

Intervention type: PROCEDURE
Intervention: Third molar surgery
Description: Surgical extraction of impacted lower third molar tooth under local anesthesia
Study: NCT00005858

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMB-9 immunotoxin
Study: NCT01907581

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of life questionnaires
Study: NCT00177541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback, pelvic floor muscle training, fMRI
Description: Biofeedback, pelvic floor muscle training, fMRI
Study: NCT04559152

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Supplementation Group
Description: Enrolled subjects received zinc capsule 20mg daily in the morning after meal for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Enrolled subjects received placebo tablet, which was inserted into capsule of the same shape and color as zinc capsule, daily in the morning after meal for 12 weeks
Study: NCT00556361

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 2 mg/Kg IV saline within 5 minutes of initiation of Cardiopulmonary bypass

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: 2 mg/Kg IV within 5 minutes of cardiopulmonary bypass
Study: NCT01096082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: 300 mg tablets, starting dose 300 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar shape, color and taste and the same number of tablets from the experimental group
Study: NCT02652247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: molecular analysis of bronchoalveolar lavage (BAL) aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: molecular analysis of bronchoalveolar lavage (BAL) aspirate
Study: NCT04463329

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional two-operator versus single operator using Jedi grip axillary brachial plexus blockage
Description: on goup C, operator used the probe and needle with different hands while an assistant controlling the syringe to aspirate or inject local anesthetic. On Group J single operator controlled the probe with one hand while controlling the needle and the syringe on the other hand with the Jedi technique. The needle was held between the index finger and the middle phalanx of the middle finger, and the syringe was held with fingers 4 and 5, with the plunger part to the thumb in the palm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional two-operator versus single operator using Jedi grip axillary brachial plexus blockage
Description: on goup C, operator used the probe and needle with different hands while an assistant controlling the syringe to aspirate or inject local anesthetic. On Group J single operator controlled the probe with one hand while controlling the needle and the syringe on the other hand with the Jedi technique. The needle was held between the index finger and the middle phalanx of the middle finger, and the syringe was held with fingers 4 and 5, with the plunger part to the thumb in the palm.
Study: NCT02548104

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACB
Description: ultrasound-guided ACB with 0.25% Bupivicaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with normal saline 15 ml

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACB + iPACK
Description: ultrasound-guided ACB with 0.25% Bupivicaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
Study: NCT01734187

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented Cinnamon Vine Powder
Description: Fermented Cinnamon Vine Powder (30g/day)
Study: NCT03169543

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: 36-hours total sleep deprivation
Study: NCT02650635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLR8 Agonist VTX-2337
Description: Given SC
Study: NCT00569465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine
Description: 1200 mg, once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: 600 mg twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 vials a day
Study: NCT03231657

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Placental biomarkers
Description: sFlt1 and P1GF levels and sFlt1/PlGF ratio
Study: NCT04830085

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Description: Hysterectomy (abdominal, vaginal or laparoscopic)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterectomy
Description: Hysterectomy (abdominal, vaginal or laparoscopic)
Study: NCT01972152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lilly Glucagon(TM) 1 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lilly Glucagon(TM) 1 mg
Study: NCT02531256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA Protector
Description: Insertion of airway device for airway management during gynaecological procedure
Study: NCT02951481

Intervention type: BEHAVIORAL
Intervention: Systematic evaluation by an ID expert.
Description: Specific bundle of measures:~1. Systematic evaluation of all patients diagnosed with CDI by an Infectious Disease expert To ensure compliance with clinical practice guidelines about specific treatment for CDI, depending on the severity of the episode and the existence of previous episodes and to optimize concomitant antibiotic therapy (antimicrobial stewardship).~2. To ensure appropriate monitoring during the period of greatest risk of relapse in order to reduce as far as possible, the number of relapses. Personalized assistance by telephone or by email for early consultation in case of recurrence of symptoms or need for a new antibiotic course.
Study: NCT01313533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyarginine
Description: Vein soak treated with polyarginine